SLC27A1 and benign prostatic hyperplasia: While palmitate treatment increased FATP1 levels in the presence of BPI, BPH, and WPI, palmitate did not affect FATP1 levels in myotubes co-incubated with WPH (Figure 6A), suggesting that WPH may reduce palmitate uptake via FATP1 into myotubes.